Vident Advisory’s Organon & Co OGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-16,532
Closed -$119K 1912
2025
Q4
$119K Sell
16,532
-7,310
-31% -$57.8K ﹤0.01% 1586
2025
Q3
$255K Sell
23,842
-4,237
-15% -$41.6K ﹤0.01% 1467
2025
Q2
$272K Sell
28,079
-9,547
-25% -$98.5K ﹤0.01% 1351
2025
Q1
$560K Sell
37,626
-1,164
-3% -$17.9K 0.01% 980
2024
Q4
$579K Buy
38,790
+23,594
+155% +$385K 0.01% 871
2024
Q3
$291K Buy
+15,196
New +$315K 0.01% 1141
2023
Q4
Sell
-74,753
Closed -$1.3M 1364
2023
Q3
$1.3M Buy
+74,753
New +$1.56M 0.04% 436

Other funds holding OGN

Vident Advisory's OGN Position: Q1 2026 in Review

Vident Advisory sold out of Organon & Co (OGN) in Q1 2026, closing a stake of 16,532 shares — an estimated $119K sold.

Vident Advisory first reported a position in OGN in Q3 2023 and held it in 7 quarters. The position peaked at $1.3M in Q3 2023. 603 funds tracked by Wall St. Rank hold OGN as of Q1 2026.

  • Vident Advisory reported no remaining Organon & Co position as of Q1 2026 after selling out during the quarter.
  • Vident Advisory sold 16,532 Organon & Co shares in Q1 2026, an estimated $119K.
  • Vident Advisory first reported a position in Organon & Co in Q3 2023 and held it in 7 quarters.
  • Vident Advisory's Organon & Co position peaked at $1.3M in Q3 2023.
  • 603 funds tracked by Wall St. Rank held Organon & Co as of Q1 2026.

Based on Vident Advisory's 13F filing for Q1 2026, filed 15 May 2026.